title: [BRAF Inhibitor-Induced Erythema Nodosum-Like Lesions].
abstract: BRAF inhibitors have been licensed for the treatment of unresectable or metastatic BRAF-mutated melanomas. In Japan, the BRAF inhibitor vemurafenib has been available since December 2014. Several adverse events induced by BRAF inhibitors have been reported, such as Stevens-Johnson syndrome, toxic epidermal necrosis, squamous cell carcinoma, secondary melanoma, and hand-foot syndrome. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as side effects that may lead to treatment discontinuation. In this report, we described the first Japanese case of erythema nodosum-like lesions induced by vemurafenib and discussed the countermeasures to this adverse reaction. Dose reduction or interruption of BRAF inhibitors should be considered on a case-by-case basis because the condition may resolve spontaneously or under symptomatic treatment. We postulate that erythema nodosum-like lesions can be controlled by careful follow-up and supportive care.
authors.affiliation: Dept. of Dermatology, Sapporo City General Hospital.
authors.forename: Keiko
authors.initials: K
authors.lastname: Shiba
authors.forename: Reine
authors.initials: R
authors.lastname: Moriuchi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Morita
authors.forename: Michio
authors.initials: M
authors.lastname: Nakamura
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Takigami
authors.forename: Satoko
authors.initials: S
authors.lastname: Shimizu
mesh_terms: D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D004893:Erythema Nodosum / Q000139:chemically induced / Q000473:pathology*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms; D000096142:Cutaneous Malignant Melanoma
chemical_list: D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf